All In Biotech

Drug Trial Radar · NCT05761795

Efficacy of IVMED-85 on Pediatric Myopia

A Randomized, Vehicle-Controlled, Double-Masked Study of the Efficacy and Safety of IVMED-85 Ophthalmic Solution for the Treatment of Pediatric Myopia

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

144

Planned (sponsor's estimate)

Start

Feb 2027

Primary completion

Feb 2029

Study completion Jun 2029

Sponsor

Lead sponsor
iVeena Delivery Systems, Inc.Industry
Sponsor type
Industry
First posted
Mar 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 5 years, up to 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of a 12-month course of IVMED-85 ophthalmic solution on the treatment of pediatric myopia. The main aims are: * Assess the efficacy of a 12-month treatment of IVMED-85 in slowing myopia progression in pediatrics * Assess the safety of a 12-month treatment of IVMED-85 Participants will use eyedrops twice a day for 12 months. Researchers will compare IVMED 85 (2 doses) to a placebo.

Conditions

  • Myopia, Progressive

Interventions

  • IVMED-85 ophthalmic solution, Low DoseDrug

    Eye drop

  • IVMED-85 ophthalmic solution, High doseDrug

    Eye drop

  • PlaceboDrug

    Eye drop

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Refractive error change from baseline at Month 12Time frame: Baseline compared to month 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.